Translating the efficacy of dapagliflozin in chronic kidney disease to lower healthcare resource utilization and costs: a medical care cost offset analysis

References

• Jha V, Garcia-Garcia G, Iseki K, et al. Chronic kidney disease: global dimension and perspectives. Lancet. 2013;382(9888):260–272. doi: 10.1016/S0140-6736(13)60687-X.
   PubMed Web of Science ®Google Scholar
• Jager KJ, Kovesdy C, Langham R, et al. A single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases. Nephrol Dial Transplant. 2019;34(11):1803–1805. doi: 10.1093/ndt/gfz174.
   PubMed Web of Science ®Google Scholar
• Bosomprah S, Bjonstad EC, Musuku J, et al. Burden of chronic kidney diseases and underlying causes in Zambia: evidence from the global burden of disease study 2019. BMC Nephrol. 2023;24(1):39. doi: 10.1186/s12882-023-03078-5.
   PubMed Web of Science ®Google Scholar
• Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet. 2013;382(9889):339–352. doi: 10.1016/S0140-6736(13)60595-4.
   PubMed Web of Science ®Google Scholar
• Darlington O, Dickerson C, Evans M, et al. Costs and healthcare resource use associated with risk of cardiovascular morbidity in patients with chronic kidney disease: evidence from a systematic literature review. Adv Ther. 2021;38(2):994–1010. doi: 10.1007/s12325-020-01607-4.
   PubMed Web of Science ®Google Scholar
• Jankowski J, Floege J, Fliser D, et al. Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options. Circulation. 2021;143(11):1157–1172. doi: 10.1161/CIRCULATIONAHA.120.050686.
   PubMed Web of Science ®Google Scholar
• Vanholder R, Annemans L, Brown E, et al. Reducing the costs of chronic kidney disease while delivering quality health care: a call to action. Nat Rev Nephrol. 2017;13(7):393–409. doi: 10.1038/nrneph.2017.63.
   PubMed Web of Science ®Google Scholar
• Jha V, Al-Ghamdi SMG, Li G, et al. Global economic burden associated with chronic kidney disease: a pragmatic review of medical costs for the inside CKD research programme. Adv Ther. 2023;40(10):4405–4420. doi: 10.1007/s12325-023-02608-9.
   PubMed Web of Science ®Google Scholar
• Nugent RA, Fathima SF, Feigl AB, et al. The burden of chronic kidney disease on developing nations: a 21st century challenge in global health. Nephron Clin Pract. 2011;118(3):c269–c277. doi: 10.1159/000321382.
   PubMedGoogle Scholar
• Sundström J, Bodegard J, Bollmann A, et al. Prevalence, outcomes, and cost of chronic kidney disease in a contemporary population of 2.4 million patients from 11 countries: the CaReMe CKD study. The Lancet Regional Health – Europe. 2022;20:100438. doi: 10.1016/j.lanepe.2022.100438.
   PubMedGoogle Scholar
• Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436–1446. doi: 10.1056/NEJMoa2024816.
   PubMed Web of Science ®Google Scholar
• Aggarwal R, Chiu N, Bhatt DL. Generalizability of DAPA-CKD to the United States. Circ Cardiovasc Qual Outcomes. 2021;14(7):e007875. doi: 10.1161/CIRCOUTCOMES.121.007875.
   PubMed Web of Science ®Google Scholar
• Wheeler DC, Stefansson BV, Batiushin M, et al. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics. Nephrol Dial Transplant. 2020;35(10):1700–1711. doi: 10.1093/ndt/gfaa234.
   PubMed Web of Science ®Google Scholar
• Heerspink HJL, Stefansson BV, Chertow GM, et al. Rationale and protocol of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) randomized controlled trial. Nephrol Dial Transplant. 2020;35(2):274–282. doi: 10.1093/ndt/gfz290.
   PubMed Web of Science ®Google Scholar
• Heerspink HJL, Cherney D, Postmus D, et al. A pre-specified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function. Kidney Int. 2022;101(1):174–184. doi: 10.1016/j.kint.2021.09.005.
   PubMed Web of Science ®Google Scholar
• Kerr M. Chronic kidney disease in England: the human and financial cost 2012. Available from: https://www.england.nhs.uk/improvement-hub/wp-content/uploads/sites/44/2017/11/Chronic-Kidney-Disease-in-England-The-Human-and-Financial-Cost.pdf.
   Google Scholar
• Kamstra R, Durkin M, Cai J, et al. Economic modelling of costs associated with outcomes reported for type 2 diabetes mellitus (T2DM) patients in the CANVAS and EMPA-REG cardiovascular outcomes trials. J Med Econ. 2019;22(3):280–287. doi: 10.1080/13696998.2018.1562817.
   PubMed Web of Science ®Google Scholar
• Manceur AM, Durkin M, Kharat A, et al. Costs associated with renal and cardiovascular events among patients with type 2 diabetes mellitus and nephropathy: a cost model based on the CREDENCE clinical trial. Curr Med Res Opin. 2020;36(4):563–570. Aprdoi: 10.1080/03007995.2019.1708285.
   PubMed Web of Science ®Google Scholar
• Tangri N, Chadban S, Cabrera C, et al. Projecting the epidemiological and economic impact of chronic kidney disease using patient-level microsimulation modelling: rationale and methods of inside CKD. Adv Ther. 2023;40(1):265–281. doi: 10.1007/s12325-022-02353-5.
   PubMed Web of Science ®Google Scholar
• Dwyer JP, Agiro A, Desai P, et al. Short-term costs in patients with chronic kidney disease treated with dapagliflozin: a retrospective cohort study. Expert Rev Pharmacoecon Outcomes Res. 2023;:1–10. doi: 10.1080/14737167.2023.2237679.
   Web of Science ®Google Scholar
• de Pouvourville G, Rossignol P, Boussahoua M, et al. Budget impact analysis of expanding gliflozin coverage in the CKD population: a french perspective. Adv Ther. 2023;40(9):3751–3769. doi: 10.1007/s12325-023-02574-2.
   PubMed Web of Science ®Google Scholar
• Alnsasra H, Tsaban G, Solomon A, et al. Dapagliflozin versus empagliflozin in patients with chronic kidney disease. Front Pharmacol. 2023;14:1227199. doi: 10.3389/fphar.2023.1227199.
   PubMed Web of Science ®Google Scholar
• Vart P, Vaduganathan M, Jongs N, et al. Estimated lifetime benefit of combined RAAS and SGLT2 inhibitor therapy in patients with albuminuric CKD without diabetes. Clin J Am Soc Nephrol. 2022;17(12):1754–1762. doi: 10.2215/CJN.08900722.
   PubMed Web of Science ®Google Scholar
• Stanifer JW, Muiru A, Jafar TH, et al. Chronic kidney disease in low- and middle-income countries. Nephrol Dial Transplant. 2016;31(6):868–874. doi: 10.1093/ndt/gfv466.
   PubMed Web of Science ®Google Scholar
• Mills KT, Xu Y, Zhang W, et al. A systematic analysis of worldwide population-based data on the global burden of chronic kidney disease in 2010. Kidney Int. 2015;88(5):950–957. doi: 10.1038/ki.2015.230.
   PubMed Web of Science ®Google Scholar
• Liyanage T, Ninomiya T, Jha V, et al. Worldwide access to treatment for end-stage kidney disease: a systematic review. Lancet. 2015;385(9981):1975–1982. doi: 10.1016/S0140-6736(14)61601-9.
   PubMed Web of Science ®Google Scholar
• Correa-Rotter R, Méndez Durán A, Vallejos A, et al. Unmet needs of CKD in latin america: a review from expert virtual working group. Kidney Int Rep. 2023;8(5):954–967. doi: 10.1016/j.ekir.2023.02.1082.
   PubMed Web of Science ®Google Scholar
• Al-Ghamdi S, Abu-Alfa A, Alotaibi T, et al. Chronic kidney disease management in the Middle East and Africa: concerns, challenges, and novel approaches. Int J Nephrol Renovasc Dis. 2023;16:103–112. doi: 10.2147/IJNRD.S363133.
   PubMed Web of Science ®Google Scholar
• Vart P, Jongs N, Wheeler DC, et al. Effectiveness and safety of dapagliflozin for black vs white patients with chronic kidney disease in North and South america: a secondary analysis of a randomized clinical trial. JAMA Netw Open. 2023;6(4):e2310877. doi: 10.1001/jamanetworkopen.2023.10877.
   PubMed Web of Science ®Google Scholar
• Vart P, Correa-Rotter R, Hou FF, et al. Efficacy and safety of dapagliflozin in patients with CKD across major geographic regions. Kidney Int Rep. 2022;7(4):699–707. doi: 10.1016/j.ekir.2022.01.1060.
   PubMed Web of Science ®Google Scholar
• McEwan P, Darlington O, Miller R, et al. Cost-effectiveness of dapagliflozin as a treatment for chronic kidney disease: a health-economic analysis of DAPA-CKD. Clin J Am Soc Nephrol. 2022;17(12):1730–1741. doi: 10.2215/CJN.03790322.
   PubMed Web of Science ®Google Scholar
• Swidan A, Elsisi GH, Ibrahim MM, et al. Projecting the potential cost-effectiveness of dapagliflozin for chronic kidney disease in Kuwait. J Med Econ. 2023;26(1):271–282. doi: 10.1080/13696998.2023.2174749.
   PubMed Web of Science ®Google Scholar
• Tisdale RL, Cusick MM, Aluri KZ, et al. Cost-effectiveness of dapagliflozin for non-diabetic chronic kidney disease. J Gen Intern Med. 2022;37(13):3380–3387. doi: 10.1007/s11606-021-07311-5.
   PubMed Web of Science ®Google Scholar
• Abegaz TM, Diaby V, Sherbeny F, et al. Cost effectiveness of dapagliflozin added to standard of care for the management of diabetic nephropathy in the USA. Clin Drug Investig. 2022;42(6):501–511. doi: 10.1007/s40261-022-01160-8.
   PubMed Web of Science ®Google Scholar
• Vareesangthip K, Deerochanawong C, Thongsuk D, et al. Cost–utility analysis of dapagliflozin as an add-on to standard of care for patients with chronic kidney disease in Thailand. Adv Ther. 2022;39(3):1279–1292. doi: 10.1007/s12325-021-02037-6.
   PubMed Web of Science ®Google Scholar
• Cusick MM, Tisdale RL, Chertow GM, et al. Population-wide screening for chronic kidney disease: a cost-effectiveness analysis. Ann Intern Med. 2023;176(6):788–797. doi: 10.7326/M22-3228.
   PubMed Web of Science ®Google Scholar
• Scheen AJ. An update on the safety of SGLT2 inhibitors. Expert Opin Drug Saf. 2019; 18(4):295–311. doi: 10.1080/14740338.2019.1602116.
   PubMed Web of Science ®Google Scholar
• International Monetary Fund. World Economic Outlook Report. 2022. Available from: https://www.imf.org/en/Publications/WEO/Issues/2022/10/11/world-economic-outlook-october-2022.
   Google Scholar